Certified by Founder
Lodge
Tome Biosciences
start up

- 14/12/2023
- Series B
- $213,000,000
Tome Biosciences is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies.
- Industry Biotechnology Research
- Website https://tome.bio/
- LinkedIn https://www.linkedin.com/company/tome-biosciences/about/